Clinical Trials Browser

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT06321484 2026-03-04

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Phase 1 Recruiting

18 enrolled

Gynecologic

Ovarian Neoplasms, Recurrence

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT06158828 2026-02-13

ABCD-NK

Phase 1/2 Recruiting

68 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Phase 2 Recruiting

14 enrolled

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06598371 2026-02-11

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Phase 1/2 Recruiting

141 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT04562129 2026-01-29

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

29 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06138587 2026-01-02

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Phase 1 Recruiting

15 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT07255664 2025-12-08

ProbeTILity

Phase 1/2 Recruiting

12 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06961357 2025-12-03

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1/2 Recruiting

36 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

3 enrolled

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Phase 2 Recruiting

130 enrolled

Gastrointestinal

Rectal Neoplasms

NCT05881525 2025-07-16

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Phase 1 Recruiting

18 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06047977 2025-07-16

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Phase 1 Recruiting

30 enrolled

Lymphocytes

NCT05086692 2025-07-09

ABILITY-1

Phase 1/2 Recruiting

115 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

128 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Clinical Trials

CIML NK Cells With Venetoclax for AML

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

SELECT-CAR-NK

ABCD-NK

TIL Therapy in cSCC and MCC

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

ProbeTILity

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

ABILITY-1

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers